Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 5 Suspected drug, ADR, outcome and causality

From: Incidence of adverse reaction of drugs used in COVID-19 management: a retrospective, observational study

Suspected drugs

Patient on treatment

ADR

Outcome

Causalitya

Recovered

Recovering

Probable

Possible

Atazanavir

167

88 (52.7%)

57

29

57

29

Chloroquine

19

7 (36.8%)

7

0

0

7

Lopinavir/ritonavir

214

78 (36.4%)

75

3

18

60

Ribavirin

7

1 (14.3%)

1

0

1

0

Hydroxychloroquine

1035

118 (11.4%)

107

11

22

96

Interferon beta-1b

91

3 (4.4%)

3

0

0

3

Tocilizumab

8

0

0

0

0

0

Favipiravir

6

0

0

0

0

0

  1. ADR is reported as n (%), where % is calculated by taking ADR/patient on treatment
  2. aNo ADR cases were classified as certain